WIRE)--Feb. 15, 2005--Do-Coop Technologies Ltd., a
privately held corporation based in Israel, announced
today the launch of its "Nano-Enhanced by Neowater(TM)"
Do-Coop Technologies manufactures largely hydrated
nano-particles (Neowater(TM)) for the Life Sciences.
Among the recently introduced products we highlight
Neowater(TM) - PCR Enhancer, Neowater(TM) - Transfection
Enhancer, and Neowater(TM) - Electrically Competent
Cells Enhancer. Do-Coop's family of products, all
based on Do-Coop's proprietary Neowater(TM) technology,
dramatically enhances existing reagents, applications
and processes to help all segments of the Life Sciences
industry to achieve the results they expect and need.
consist of largely hydrated nano-particles that lead
to several important benefits for research, diagnostics
and bio-pharma applications. The hydrated nano-particles,
like non-ionic detergent derived micelles, reduce
the entropy of aqueous solutions and mimic intracellular
water. In addition, by design, they exhibit hydrophobic
The non-ionic Neowater(TM)
works by coating components at their molecular level,
thus exposing, increasing and/or enhancing those specific
surfaces which are required for a specific reaction
but are normally not available to interact (e.g. GC-rich
DNA). Therefore, very small volumes of Neowater(TM),
and reduced component's concentrations or amounts,
are needed for a reaction when using Neowater(TM).
Neowater(TM) allows for (low-volume) miniaturization
of Life Sciences products, applications and processes.
significantly accelerate and improve the efficiency
of biological reactions.
The "Nano-Enhanced by
Neowater(TM)" partnership program
The partnership program leverages
the inherent advantages of Do-Coop's Nano-technology,
Neowater(TM), by enabling well-established Life Sciences
industry players to dramatically enhance their already
successful product lines to the benefit of their customers.
"Our recent research has
indicated that there are critical roadblocks preventing
significant advances in research, diagnostics and
therapeutics in the bio-pharma industry. As an example,
despite the impressive advances in genetic-based therapeutics
research, there is still a large, still unbridgeable
gap to translate these initial R&D achievements
into viable, commercial products that will one day
cure human diseases at their genetic root.
"Furthermore, our research
uncovered that if the Life Sciences industry is to
achieve a breakthrough jump in price-performance,
as recently seen in the Microelectronics industry,
there is an urgent need to drive miniaturization of
"This is what the entire
Life Sciences industry has been expecting for a long
time, and hoping that Nano-technology would be the
awaited solution to address and solve these urgent
combined with our partners' existing products and
processes, allows the Life Science industry to deliver
on their promise of genetic-based therapeutics, and
for Nano-technology to become the key that unlocks
the previously closed door to miniaturization in the
Life Sciences industry. Neowater(TM) will turn our
partner's offering from ordinary into extraordinary,"
said Eran Gabbai, founder and CTO of Do-Coop Technologies,
and the inventor of Neowater(TM).
has been identified and recognized by Frost &
Sullivan. Do-Coop received the Frost & Sullivan's
coveted "2004 Enabling Technology in Nano-medicine"
award, and will be receiving Frost & Sullivan's
"2005 Excellence in Medicine Award" this
week in London.
Do-Coop Technologies Ltd.
Eran Gabbai, +972-3-533-3804